{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T07:31:37Z","timestamp":1776843097979,"version":"3.51.2"},"reference-count":16,"publisher":"Open Exploration Publishing","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/doi.org\/10.37349\/Open_Exploration_Crossmark_Policy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Background: Multiple myeloma (MM) is a hematologic malignancy characterized by the clonal proliferation of malignant plasma cells in the bone marrow, constituting approximately 13% of all hematologic malignancies. Isatuximab is a monoclonal antibody targeting the CD38 protein on myeloma cells, causing cell death through various immune-mediated mechanisms. Clinical trials have shown that adding isatuximab to standard regimens for MM significantly enhances efficacy but introduces some notable toxicities. The purpose of this study is to determine the risk of pneumonia, upper respiratory tract infections (URTIs), and venous thromboembolism (VTE) in patients with MM treated with isatuximab.\nMethods: We conducted a comprehensive literature search using Medline, Embase, and Cochrane databases from inception through July 22nd, 2024. Phase III randomized controlled trials (RCTs) utilizing isatuximab in newly diagnosed MM (NDMM) and relapsed and refractory MM (RRMM) reporting pneumonia, URTIs, and VTE as adverse events were included. Mantel-Haenszel (MH) method was used to calculate the estimated pooled risk ratio (RR) with 95% confidence interval (CI). Heterogeneity was assessed with Cochran\u2019s Q-statistic. Random effects model was applied.\nResults: A total of 1,044 patients from three phase III RCTs (ICARIA-MM, IKEMA, IMROZ) were included for pneumonia and URTI analysis, while 1,403 patients from three trials (IKEMA, IMROZ, GMMG-HD7) were included for VTE evaluation. The incidence of any-grade pneumonia was higher in the isatuximab group (30.1% vs. 23.2%; RR, 1.31; 95% CI 1.06\u20131.61; P = 0.01), as was high-grade pneumonia (20.8% vs. 15.3%; RR, 1.38; 95% CI 1.06\u20131.81; P = 0.02). No statistically significant differences were observed between the isatuximab and control groups for any-grade URTIs, high-grade URTIs, or VTE.\nDiscussion: This meta-analysis highlights a significant increase in the incidence of pneumonia with the addition of isatuximab to standard myeloma regimens, underscoring the need for routine antibiotic prophylaxis, thromboprophylaxis, vigilant monitoring and early intervention to mitigate these risks.<\/jats:p>","DOI":"10.37349\/etat.2025.1002300","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T03:47:42Z","timestamp":1742442462000},"update-policy":"https:\/\/doi.org\/10.37349\/open_exploration_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A systematic review and meta-analysis of phase III randomized controlled trials to assess the risk of pneumonia, URTIs, and VTE in multiple myeloma patients treated with isatuximab"],"prefix":"10.37349","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3625-1790","authenticated-orcid":false,"given":"Daniel Thomas","family":"Jones","sequence":"first","affiliation":[{"name":"Touro University Nevada College of Osteopathic Medicine, Las Vegas, NV 89014, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3085-1549","authenticated-orcid":false,"given":"Hazem","family":"Aboaid","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV 89106, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5776-0222","authenticated-orcid":false,"given":"Ramaditya","family":"Srinivasmurthy","sequence":"additional","affiliation":[{"name":"Touro University Nevada College of Osteopathic Medicine, Las Vegas, NV 89014, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5689-026X","authenticated-orcid":false,"given":"Kevin","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Touro University Nevada College of Osteopathic Medicine, Las Vegas, NV 89014, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4637-5733","authenticated-orcid":false,"given":"Rishi Kumar","family":"Nanda","sequence":"additional","affiliation":[{"name":"Touro University Nevada College of Osteopathic Medicine, Las Vegas, NV 89014, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8514-2781","authenticated-orcid":false,"given":"Jason","family":"Ta","sequence":"additional","affiliation":[{"name":"Touro University Nevada College of Osteopathic Medicine, Las Vegas, NV 89014, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1903-0042","authenticated-orcid":false,"given":"Benjamin Tzer-Ming","family":"Chuang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, St. Rose Dominican Hospital, San Martin Campus, Las Vegas, NV 89113, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3799-7067","authenticated-orcid":false,"given":"Yin Mon","family":"Myat","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, One Brooklyn Health\u2014Interfaith Medical Center Campus, Brooklyn, NY 11213, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1848-0918","authenticated-orcid":false,"given":"Aishwarya","family":"Hanspal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Sunrise Health GME Consortium, Las Vegas, NV 89128, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1518-1097","authenticated-orcid":false,"given":"Kyaw Zin","family":"Thein","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Comprehensive Cancer Centers of Nevada, Central Valley, Las Vegas, NV 89169, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5508-1472","authenticated-orcid":false,"given":"Thura Win","family":"Htut","sequence":"additional","affiliation":[{"name":"Department of Haematology, Aberdeen Royal Infirmary, AB25 2ZN Aberdeen, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"21850","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Cordero HM, Malagon JZ, Osorio LC, Mendoza AR, Ram\u00edrez AP, Idarraga JO, et al. Multiple Myeloma Mortality Incidence Prevalence of Disease - Mmy Mind Study. Blood. 2020;136:10\u20131. [DOI: 10.1182\/blood-2020-142376]","DOI":"10.1182\/blood-2020-142376"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Costa LJ, Brill IK, Omel J, Godby K, Kumar SK, Brown EE. Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. Blood Adv. 2017;1:282\u20137. [PMID: 29296944 PMCID: PMC5727774 DOI: 10.1182\/bloodadvances.2016002493]","DOI":"10.1182\/bloodadvances.2016002493"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Cornell RF, Gandhi UH, Lakshman A, Gahvari Z, Jagosky MH, McGehee E, et al. Subsequent Treatment Outcomes of Multiple Myeloma Refractory to CD38-Monoclonal Antibody Therapy. Blood. 2018;132:2015. [DOI: 10.1182\/blood-2018-99-115078]","DOI":"10.1182\/blood-2018-99-115078"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Perez de Acha O, Reiman L, Jayabalan DS, Walker ZJ, Bosma G, Keller AL, et al. CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies. Blood Adv. 2023;7:6430\u201340. [PMID: 37648670 PMCID: PMC10598487 DOI: 10.1182\/bloodadvances.2023010162]","DOI":"10.1182\/bloodadvances.2023010162"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"van de Donk NWCJ, Richardson PG, Malavasi F. CD38 antibodies in multiple myeloma: back to the future. Blood. 2018;131:13\u201329. [PMID: 29118010 DOI: 10.1182\/blood-2017-06-740944]","DOI":"10.1182\/blood-2017-06-740944"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Thet A, Myint PT, Hadid T. Safety and Tolerability of Anti-CD38 Monoclonal Antibodies (mAb) in Multiple Myeloma. Blood. 2022;140:12552\u20133. [DOI: 10.1182\/blood-2022-166989]","DOI":"10.1182\/blood-2022-166989"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"McCurdy A, Seow H, Pond GR, Gayowsky A, Chakraborty R, Visram A, et al. Causes of Death Among Patients with Multiple Myeloma: A 10 Year Longitudinal Analysis of a Population-Based Cohort in Ontario, Canada. Blood. 2022;140:427\u20139. [DOI: 10.1182\/blood-2022-157815]","DOI":"10.1182\/blood-2022-157815"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Blimark C, Holmberg E, Mellqvist UH, Landgren O, Bj\u00f6rkholm M, Hultcrantz M, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100:107\u201313. [PMID: 25344526 PMCID: PMC4281323 DOI: 10.3324\/haematol.2014.107714]","DOI":"10.3324\/haematol.2014.107714"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"De Stefano V, Larocca A, Carpenedo M, Cavo M, Di Raimondo F, Falanga A, et al. Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel. Haematologica. 2022;107:2536\u201347. [PMID: 35861017 PMCID: PMC9614522 DOI: 10.3324\/haematol.2022.280893]","DOI":"10.3324\/haematol.2022.280893"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Htut TW, Win MA, Han MM, Thein KZ. Meta-Analysis of Randomized Controlled Trials to Evaluate the Incidence of Pneumonia, Upper Respiratory Tract Infections and Febrile Neutropenia in Patients with Multiple Myeloma Treated with Isatuximab. Blood. 2023;142:7379. [DOI: 10.1182\/blood-2023-178302]","DOI":"10.1182\/blood-2023-178302"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Vassilopoulos S, Vassilopoulos A, Kalligeros M, Shehadeh F, Mylonakis E. Cumulative Incidence and Relative Risk of Infection in Patients With Multiple Myeloma Treated With Anti-CD38 Monoclonal Antibody-Based Regimens: A Systematic Review and Meta-analysis. Open Forum Infect Dis. 2022;9:ofac574. [PMID: 36438616 PMCID: PMC9685179 DOI: 10.1093\/ofid\/ofac574]","DOI":"10.1093\/ofid\/ofac574"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Balmaceda N, Aziz M, Chandrasekar VT, McClune B, Kambhampati S, Shune L, et al. Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019. BMC Cancer. 2021;21:730. [ PMID: 34172037 PMCID: PMC8233183 DOI: 10.1186\/s12885-021-08451-x]","DOI":"10.1186\/s12885-021-08451-x"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, et al.; ICARIA-MM study group. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394:2096\u2013107. [PMID: 31735560 DOI: 10.1016\/S0140-6736(19)32556-5]","DOI":"10.1016\/s1470-2045(22)00019-5"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, et al.; IKEMA study group. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021;397:2361\u201371. [PMID: 34097854 DOI: 10.1016\/S0140-6736(21)00592-4]","DOI":"10.1016\/j.htct.2020.10.439"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Facon T, Dimopoulos MA, Leleu XP, Beksac M, Pour L, H\u00e1jek R, et al.; IMROZ Study Group. Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2024;391:1597\u2013609. [PMID: 38832972 DOI: 10.1056\/NEJMoa2400712]","DOI":"10.1016\/s2152-2650(24)01890-1"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Goldschmidt H, Mai EK, Bertsch U, Fenk R, Nievergall E, Tichy D, et al.; German-Speaking Myeloma Multicenter Group (GMMG) HD7 investigators. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. Lancet Haematol. 2022;9:e810\u201321. [PMID: 36328040 DOI: 10.1016\/S2352-3026(22)00263-0]","DOI":"10.1182\/blood-2021-145097"}],"container-title":["Exploration of Targeted Anti-tumor Therapy"],"original-title":[],"link":[{"URL":"https:\/\/www.explorationpub.com\/Journals\/etat\/Article\/1002300","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T03:47:48Z","timestamp":1742442468000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.explorationpub.com\/Journals\/etat\/Article\/1002300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":16,"URL":"https:\/\/doi.org\/10.37349\/etat.2025.1002300","archive":["Portico","Portico"],"relation":{},"ISSN":["2692-3114"],"issn-type":[{"value":"2692-3114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]},"assertion":[{"value":"2024-12-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-2-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-3-19","order":2,"name":"published_online","label":"Published Online","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"1002300"}}